

81.25 **ARTICLE 8**
81.26 **CONTROLLED SUBSTANCES**

81.27 Section 1. Minnesota Statutes 2014, section 152.02, subdivision 2, is amended to read:

81.28 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this
81.29 subdivision.

81.30 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of
81.31 the following substances, including their analogs, isomers, esters, ethers, salts, and salts
81.32 of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
81.33 ethers, and salts is possible:

81.34 (1) acetylmethadol;

81.35 (2) allylprodine;

82.1 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
82.2 levomethadyl acetate);

82.3 (4) alphameprodine;

82.4 (5) alphamethadol;

82.5 (6) alpha-methylfentanyl benzethidine;

82.6 (7) betacetylmethadol;

82.7 (8) betameprodine;

82.8 (9) betamethadol;

82.9 (10) betaprodine;

82.10 (11) clonitazene;

82.11 (12) dextromoramide;

82.12 (13) diampromide;

82.13 (14) diethylambutene;

82.14 (15) difenoxin;

82.15 (16) dimenoxadol;

82.16 (17) dimepheptanol;

82.17 (18) dimethylambutene;

82.18 (19) dioxaphetyl butyrate;

82.19 (20) dipipanone;

FROM SF 1219

1.5 Section 1. Minnesota Statutes 2014, section 152.02, subdivision 2, is amended to read:

1.6 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this
1.7 subdivision.

1.8 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of
1.9 the following substances, including their analogs, isomers, esters, ethers, salts, and salts
1.10 of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
1.11 ethers, and salts is possible:

1.12 (1) acetylmethadol;

1.13 (2) allylprodine;

1.14 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
1.15 levomethadyl acetate);

1.16 (4) alphameprodine;

1.17 (5) alphamethadol;

1.18 (6) alpha-methylfentanyl benzethidine;

1.19 (7) betacetylmethadol;

1.20 (8) betameprodine;

1.21 (9) betamethadol;

1.22 (10) betaprodine;

1.23 (11) clonitazene;

1.24 (12) dextromoramide;

2.1 (13) diampromide;

2.2 (14) diethylambutene;

2.3 (15) difenoxin;

2.4 (16) dimenoxadol;

2.5 (17) dimepheptanol;

2.6 (18) dimethylambutene;

2.7 (19) dioxaphetyl butyrate;

2.8 (20) dipipanone;

82.20 (21) ethylmethylthiambutene;
82.21 (22) etonitazene;
82.22 (23) etoxeridine;
82.23 (24) furethidine;
82.24 (25) hydroxypethidine;
82.25 (26) ketobemidone;
82.26 (27) levomoramide;
82.27 (28) levophenacilmorphan;
82.28 (29) 3-methylfentanyl;
82.29 (30) acetyl-alpha-methylfentanyl;
82.30 (31) alpha-methylthiofentanyl;
82.31 (32) benzylfentanyl beta-hydroxyfentanyl;
82.32 (33) beta-hydroxy-3-methylfentanyl;
82.33 (34) 3-methylthiofentanyl;
82.34 (35) thenylfentanyl;
82.35 (36) thiofentanyl;
82.36 (37) para-fluorofentanyl;
83.1 (38) morpheridine;
83.2 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
83.3 (40) noracymethadol;
83.4 (41) norlevorphanol;
83.5 (42) normethadone;
83.6 (43) norpipanone;
83.7 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
83.8 (45) phenadoxone;
83.9 (46) phenampromide;
83.10 (47) phenomorphan;
83.11 (48) phenoperidine;

2.9 (21) ethylmethylthiambutene;
2.10 (22) etonitazene;
2.11 (23) etoxeridine;
2.12 (24) furethidine;
2.13 (25) hydroxypethidine;
2.14 (26) ketobemidone;
2.15 (27) levomoramide;
2.16 (28) levophenacilmorphan;
2.17 (29) 3-methylfentanyl;
2.18 (30) acetyl-alpha-methylfentanyl;
2.19 (31) alpha-methylthiofentanyl;
2.20 (32) benzylfentanyl beta-hydroxyfentanyl;
2.21 (33) beta-hydroxy-3-methylfentanyl;
2.22 (34) 3-methylthiofentanyl;
2.23 (35) thenylfentanyl;
2.24 (36) thiofentanyl;
2.25 (37) para-fluorofentanyl;
2.26 (38) morpheridine;
2.27 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
2.28 (40) noracymethadol;
2.29 (41) norlevorphanol;
2.30 (42) normethadone;
2.31 (43) norpipanone;
2.32 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
2.33 (45) phenadoxone;
2.34 (46) phenampromide;
2.35 (47) phenomorphan;
2.36 (48) phenoperidine;

83.12 (49) piritramide;
83.13 (50) proheptazine;
83.14 (51) properidine;
83.15 (52) propiram;
83.16 (53) racemoramide;
83.17 (54) tilidine;
83.18 (55) trimeperidine;
83.19 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl).
83.20 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
83.21 and salts of isomers, unless specifically excepted or unless listed in another schedule,
83.22 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
83.23 (1) acetorphine;
83.24 (2) acetyldihydrocodeine;
83.25 (3) benzylmorphine;
83.26 (4) codeine methylbromide;
83.27 (5) codeine-n-oxide;
83.28 (6) cyprenorphine;
83.29 (7) desomorphine;
83.30 (8) dihydromorphine;
83.31 (9) drotebanol;
83.32 (10) etorphine;
83.33 (11) heroin;
83.34 (12) hydromorphanol;
83.35 (13) methyldesorphine;
83.36 (14) methyldihydromorphine;
84.1 (15) morphine methylbromide;
84.2 (16) morphine methylsulfonate;
84.3 (17) morphine-n-oxide;
84.4 (18) myrophine;

3.1 (49) piritramide;
3.2 (50) proheptazine;
3.3 (51) properidine;
3.4 (52) propiram;
3.5 (53) racemoramide;
3.6 (54) tilidine;
3.7 (55) trimeperidine;
3.8 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl).
3.9 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
3.10 and salts of isomers, unless specifically excepted or unless listed in another schedule,
3.11 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
3.12 (1) acetorphine;
3.13 (2) acetyldihydrocodeine;
3.14 (3) benzylmorphine;
3.15 (4) codeine methylbromide;
3.16 (5) codeine-n-oxide;
3.17 (6) cyprenorphine;
3.18 (7) desomorphine;
3.19 (8) dihydromorphine;
3.20 (9) drotebanol;
3.21 (10) etorphine;
3.22 (11) heroin;
3.23 (12) hydromorphanol;
3.24 (13) methyldesorphine;
3.25 (14) methyldihydromorphine;
3.26 (15) morphine methylbromide;
3.27 (16) morphine methylsulfonate;
3.28 (17) morphine-n-oxide;
3.29 (18) myrophine;

84.5 (19) nicocodeine;
84.6 (20) nicomorphine;
84.7 (21) normorphine;
84.8 (22) pholcodine;
84.9 (23) thebacon.
84.10 (d) Hallucinogens. Any material, compound, mixture or preparation which contains
84.11 any quantity of the following substances, their analogs, salts, isomers (whether optical,
84.12 positional, or geometric), and salts of isomers, unless specifically excepted or unless listed
84.13 in another schedule, whenever the existence of the analogs, salts, isomers, and salts of
84.14 isomers is possible:
84.15 (1) methylenedioxy amphetamine;
84.16 (2) methylenedioxymethamphetamine;
84.17 (3) methylenedioxy-N-ethylamphetamine (MDEA);
84.18 (4) n-hydroxy-methylenedioxyamphetamine;
84.19 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
84.20 (6) 2,5-dimethoxyamphetamine (2,5-DMA);
84.21 (7) 4-methoxyamphetamine;
84.22 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
84.23 (9) alpha-ethyltryptamine;
84.24 (10) bufotenine;
84.25 (11) diethyltryptamine;
84.26 (12) dimethyltryptamine;
84.27 (13) 3,4,5-trimethoxyamphetamine;
84.28 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
84.29 (15) ibogaine;
84.30 (16) lysergic acid diethylamide (LSD);
84.31 (17) mescaline;
84.32 (18) parahexyl;
84.33 (19) N-ethyl-3-piperidyl benzilate;

3.30 (19) nicocodeine;
3.31 (20) nicomorphine;
3.32 (21) normorphine;
3.33 (22) pholcodine;
3.34 (23) thebacon.
3.35 (d) Hallucinogens. Any material, compound, mixture or preparation which contains
3.36 any quantity of the following substances, their analogs, salts, isomers (whether optical,
4.1 positional, or geometric), and salts of isomers, unless specifically excepted or unless listed
4.2 in another schedule, whenever the existence of the analogs, salts, isomers, and salts of
4.3 isomers is possible:
4.4 (1) methylenedioxy amphetamine;
4.5 (2) methylenedioxymethamphetamine;
4.6 (3) methylenedioxy-N-ethylamphetamine (MDEA);
4.7 (4) n-hydroxy-methylenedioxyamphetamine;
4.8 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
4.9 (6) 2,5-dimethoxyamphetamine (2,5-DMA);
4.10 (7) 4-methoxyamphetamine;
4.11 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
4.12 (9) alpha-ethyltryptamine;
4.13 (10) bufotenine;
4.14 (11) diethyltryptamine;
4.15 (12) dimethyltryptamine;
4.16 (13) 3,4,5-trimethoxyamphetamine;
4.17 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
4.18 (15) ibogaine;
4.19 (16) lysergic acid diethylamide (LSD);
4.20 (17) mescaline;
4.21 (18) parahexyl;
4.22 (19) N-ethyl-3-piperidyl benzilate;

84.34 (20) N-methyl-3-piperidyl benzilate;
84.35 (21) psilocybin;
84.36 (22) psilocyn;
85.1 (23) tenocyclidine (TCP or TCP);
85.2 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
85.3 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
85.4 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
85.5 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
85.6 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
85.7 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
85.8 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
85.9 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
85.10 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
85.11 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
85.12 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
85.13 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
85.14 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
85.15 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
85.16 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
85.17 (2-CB-FLY);
85.18 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
85.19 (40) alpha-methyltryptamine (AMT);
85.20 (41) N,N-diisopropyltryptamine (DiPT);
85.21 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
85.22 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
85.23 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
85.24 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
85.25 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);

4.23 (20) N-methyl-3-piperidyl benzilate;
4.24 (21) psilocybin;
4.25 (22) psilocyn;
4.26 (23) tenocyclidine (TCP or TCP);
4.27 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
4.28 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
4.29 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
4.30 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
4.31 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
4.32 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
4.33 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
4.34 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
4.35 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
4.36 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
5.1 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
5.2 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
5.3 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
5.4 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
5.5 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
5.6 (2-CB-FLY);
5.7 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
5.8 (40) alpha-methyltryptamine (AMT);
5.9 (41) N,N-diisopropyltryptamine (DiPT);
5.10 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
5.11 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
5.12 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
5.13 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
5.14 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);

85.26 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
 85.27 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
 85.28 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
 85.29 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
 85.30 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
 85.31 (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
 85.32 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
 85.33 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
 85.34 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
 85.35 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
 85.36 (57) methoxetamine (MXE);
 86.1 (58) 5-iodo-2-aminoindane (5-IAI);
 86.2 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
 86.3 (60) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
 86.4 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
 86.5 (25B-NBOMe);
 86.6 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
 86.7 (25C-NBOMe);
 86.8 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
 86.9 (25I-NBOMe);
 86.10 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
 86.11 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
 86.12 (e) Peyote. All parts of the plant presently classified botanically as Lophophora
 86.13 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part
 86.14 of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation
 86.15 of the plant, its seeds or extracts. The listing of peyote as a controlled substance in
 86.16 Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies
 86.17 of the American Indian Church, and members of the American Indian Church are exempt
 86.18 from registration. Any person who manufactures peyote for or distributes peyote to the
 86.19 American Indian Church, however, is required to obtain federal registration annually and
 86.20 to comply with all other requirements of law.

5.15 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
 5.16 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
 5.17 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
 5.18 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
 5.19 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
 5.20 (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
 5.21 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
 5.22 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
 5.23 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
 5.24 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
 5.25 (57) methoxetamine (MXE);
 5.26 (58) 5-iodo-2-aminoindane (5-IAI);
 5.27 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
 5.28 (60) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
 5.29 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
 5.30 (25B-NBOMe);
 5.31 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
 5.32 (25C-NBOMe);
 5.33 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
 5.34 (25I-NBOMe);
 5.35 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
 5.36 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
 6.1 (e) Peyote. All parts of the plant presently classified botanically as Lophophora
 6.2 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part
 6.3 of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation
 6.4 of the plant, its seeds or extracts. The listing of peyote as a controlled substance in
 6.5 Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies
 6.6 of the American Indian Church, and members of the American Indian Church are exempt
 6.7 from registration. Any person who manufactures peyote for or distributes peyote to the
 6.8 American Indian Church, however, is required to obtain federal registration annually and
 6.9 to comply with all other requirements of law.

86.21 (f) Central nervous system depressants. Unless specifically excepted or unless listed
86.22 in another schedule, any material compound, mixture, or preparation which contains any
86.23 quantity of the following substances, their analogs, salts, isomers, and salts of isomers
86.24 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

86.25 (1) mecloqualone;

86.26 (2) methaqualone;

86.27 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;

86.28 (4) flunitrazepam.

86.29 (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
86.30 material compound, mixture, or preparation which contains any quantity of the following
86.31 substances, their analogs, salts, isomers, and salts of isomers whenever the existence of
86.32 the analogs, salts, isomers, and salts of isomers is possible:

86.33 (1) aminorex;

86.34 (2) cathinone;

86.35 (3) fenethylamine;

86.36 (4) methcathinone;

87.1 (5) methylaminorex;

87.2 (6) N,N-dimethylamphetamine;

87.3 (7) N-benzylpiperazine (BZP);

87.4 (8) methylmethcathinone (mephedrone);

87.5 (9) 3,4-methylenedioxy-N-methylcathinone (methylone);

87.6 (10) methoxymethcathinone (methedrone);

87.7 (11) methylenedioxypropylamphetamine (MDPV);

87.8 (12) ~~fluoromethcathinone~~ 3-fluoro-N-methylcathinone (3-FMC);

87.9 (13) methylethcathinone (MEC);

87.10 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);

87.11 (15) dimethylmethcathinone (DMMC);

87.12 (16) fluoroamphetamine;

87.13 (17) fluoromethamphetamine;

87.14 (18) α -methylaminobutyrophenone (MABP or buphedrone);

6.10 (f) Central nervous system depressants. Unless specifically excepted or unless listed
6.11 in another schedule, any material compound, mixture, or preparation which contains any
6.12 quantity of the following substances, their analogs, salts, isomers, and salts of isomers
6.13 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

6.14 (1) mecloqualone;

6.15 (2) methaqualone;

6.16 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;

6.17 (4) flunitrazepam.

6.18 (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
6.19 material compound, mixture, or preparation which contains any quantity of the following
6.20 substances, their analogs, salts, isomers, and salts of isomers whenever the existence of
6.21 the analogs, salts, isomers, and salts of isomers is possible:

6.22 (1) aminorex;

6.23 (2) cathinone;

6.24 (3) fenethylamine;

6.25 (4) methcathinone;

6.26 (5) methylaminorex;

6.27 (6) N,N-dimethylamphetamine;

6.28 (7) N-benzylpiperazine (BZP);

6.29 (8) methylmethcathinone (mephedrone);

6.30 (9) 3,4-methylenedioxy-N-methylcathinone (methylone);

6.31 (10) methoxymethcathinone (methedrone);

6.32 (11) methylenedioxypropylamphetamine (MDPV);

6.33 (12) ~~fluoromethcathinone~~ 3-fluoro-N-methylcathinone (3-FMC);

6.34 (13) methylethcathinone (MEC);

6.35 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);

6.36 (15) dimethylmethcathinone (DMMC);

7.1 (16) fluoroamphetamine;

7.2 (17) fluoromethamphetamine;

7.3 (18) α -methylaminobutyrophenone (MABP or buphedrone);

87.15 (19) β -keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone)
 87.16 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
 87.17 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
 87.18 (21) naphthylpyrovalerone (naphyrone) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)
 87.19 pentan-1-one (naphthylpyrovalerone or naphyrone);
 87.20 (22) (RS)-1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP or
 87.21 alpha-pyrrolidinoveralero phenone (alpha-pyrrolidinopentiophenone (alpha-PVP));
 87.22 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or
 87.23 MPHP); and
 87.24 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
 87.25 (25) 4-methyl-N-ethylcathinone (4-MEC);
 87.26 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
 87.27 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
 87.28 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
 87.29 (29) 4-fluoro-N-methylcathinone (4-FMC);
 87.30 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
 87.31 (31) alpha-pyrrolidinobutiophenone (α -PBP);
 87.32 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
 87.33 (33) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); and
 87.34 ~~(24)~~ (34) any other substance, except bupropion or compounds listed under a
 87.35 different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
 88.1 at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
 88.2 the compound is further modified in any of the following ways:
 88.3 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
 88.4 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
 88.5 system by one or more other univalent substituents;
 88.6 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
 88.7 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
 88.8 methoxybenzyl groups; or
 88.9 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

7.4 (19) β -keto-N-methylbenzodioxolylpropylamine (bk-MBDB or
 7.5 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
 7.6 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
 7.7 (21) naphthylpyrovalerone (naphyrone) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)
 7.8 pentan-1-one (naphthylpyrovalerone or naphyrone);
 7.9 (22) (RS)-1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP or
 7.10 alpha-pyrrolidinoveralero phenone (alpha-pyrrolidinopentiophenone (alpha-PVP));
 7.11 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or
 7.12 MPHP); and
 7.13 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
 7.14 (25) 4-methyl-N-ethylcathinone (4-MEC);
 7.15 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
 7.16 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
 7.17 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
 7.18 (29) 4-fluoro-N-methylcathinone (4-FMC);
 7.19 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
 7.20 (31) alpha-pyrrolidinobutiophenone (α -PBP);
 7.21 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
 7.22 (33) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); and
 7.23 ~~(24)~~ (34) any other substance, except bupropion or compounds listed under a
 7.24 different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
 7.25 at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
 7.26 the compound is further modified in any of the following ways:
 7.27 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
 7.28 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
 7.29 system by one or more other univalent substituents;
 7.30 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
 7.31 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
 7.32 methoxybenzyl groups; or
 7.33 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

88.10 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
 88.11 specifically excepted or unless listed in another schedule, any natural or synthetic material,
 88.12 compound, mixture, or preparation that contains any quantity of the following substances,
 88.13 their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
 88.14 whenever the existence of the isomers, esters, ethers, or salts is possible:

88.15 (1) marijuana;

88.16 (2) tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis*,
 88.17 synthetic equivalents of the substances contained in the cannabis plant or in the
 88.18 resinous extractives of the plant, or synthetic substances with similar chemical structure
 88.19 and pharmacological activity to those substances contained in the plant or resinous
 88.20 extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
 88.21 tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;

88.22 (3) synthetic cannabinoids, including the following substances:

88.23 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
 88.24 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
 88.25 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
 88.26 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
 88.27 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
 88.28 naphthoylindoles include, but are not limited to:

88.29 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

88.30 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

88.31 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

88.32 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

88.33 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

88.34 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

88.35 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

88.36 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

89.1 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

89.2 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

89.3 (ii) Naphthylmethylindoles, which are any compounds containing a
 89.4 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
 89.5 of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
 89.6 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
 89.7 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
 89.8 ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

7.34 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
 7.35 specifically excepted or unless listed in another schedule, any natural or synthetic material,
 7.36 compound, mixture, or preparation that contains any quantity of the following substances,
 8.1 their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
 8.2 whenever the existence of the isomers, esters, ethers, or salts is possible:

8.3 (1) marijuana;

8.4 (2) tetrahydrocannabinols naturally contained in a plant of the genus *Cannabis*,
 8.5 synthetic equivalents of the substances contained in the cannabis plant or in the
 8.6 resinous extractives of the plant, or synthetic substances with similar chemical structure
 8.7 and pharmacological activity to those substances contained in the plant or resinous
 8.8 extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
 8.9 tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;

8.10 (3) synthetic cannabinoids, including the following substances:

8.11 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
 8.12 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
 8.13 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
 8.14 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
 8.15 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
 8.16 naphthoylindoles include, but are not limited to:

8.17 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

8.18 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

8.19 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

8.20 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

8.21 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

8.22 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

8.23 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

8.24 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

8.25 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

8.26 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

8.27 (ii) Naphthylmethylindoles, which are any compounds containing a
 8.28 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
 8.29 of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
 8.30 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
 8.31 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
 8.32 ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

- 89.9 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
- 89.10 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
- 89.11 (iii) Naphthoypyrroles, which are any compounds containing a
- 89.12 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
- 89.13 pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 89.14 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
- 89.15 further substituted in the pyrrole ring to any extent, whether or not substituted in the
- 89.16 naphthyl ring to any extent. Examples of naphthoypyrroles include, but are not limited to,
- 89.17 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
- 89.18 (iv) Naphthylmethylindenes, which are any compounds containing a
- 89.19 naphthylideneindene structure with substitution at the 3-position of the indene
- 89.20 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 89.21 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
- 89.22 substituted in the indene ring to any extent, whether or not substituted in the naphthyl
- 89.23 ring to any extent. Examples of naphthylmethylindenes include, but are not limited to,
- 89.24 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
- 89.25 (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
- 89.26 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
- 89.27 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 89.28 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
- 89.29 any extent, whether or not substituted in the phenyl ring to any extent. Examples of
- 89.30 phenylacetylindoles include, but are not limited to:
- 89.31 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
- 89.32 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
- 89.33 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
- 89.34 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
- 89.35 (vi) Cyclohexylphenols, which are compounds containing a
- 89.36 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
- 90.1 of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 90.2 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
- 90.3 substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
- 90.4 but are not limited to:
- 90.5 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
- 90.6 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
- 90.7 (Cannabicyclohexanol or CP 47,497 C8 homologue);

- 8.33 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
- 8.34 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
- 8.35 (iii) Naphthoypyrroles, which are any compounds containing a
- 8.36 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
- 9.1 pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 9.2 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
- 9.3 further substituted in the pyrrole ring to any extent, whether or not substituted in the
- 9.4 naphthyl ring to any extent. Examples of naphthoypyrroles include, but are not limited to,
- 9.5 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
- 9.6 (iv) Naphthylmethylindenes, which are any compounds containing a
- 9.7 naphthylideneindene structure with substitution at the 3-position of the indene
- 9.8 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 9.9 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
- 9.10 substituted in the indene ring to any extent, whether or not substituted in the naphthyl
- 9.11 ring to any extent. Examples of naphthylmethylindenes include, but are not limited to,
- 9.12 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
- 9.13 (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
- 9.14 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
- 9.15 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 9.16 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
- 9.17 any extent, whether or not substituted in the phenyl ring to any extent. Examples of
- 9.18 phenylacetylindoles include, but are not limited to:
- 9.19 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
- 9.20 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
- 9.21 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
- 9.22 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
- 9.23 (vi) Cyclohexylphenols, which are compounds containing a
- 9.24 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
- 9.25 of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 9.26 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
- 9.27 substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
- 9.28 but are not limited to:
- 9.29 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
- 9.30 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
- 9.31 (Cannabicyclohexanol or CP 47,497 C8 homologue);

90.8 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
90.9 -phenol (CP 55,940).

90.10 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
90.11 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
90.12 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
90.13 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
90.14 any extent and whether or not substituted in the phenyl ring to any extent. Examples of
90.15 benzoylindoles include, but are not limited to:

90.16 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

90.17 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

90.18 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
90.19 (WIN 48,098 or Pravadoline).

90.20 (viii) Others specifically named:

90.21 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
90.22 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

90.23 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
90.24 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

90.25 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
90.26 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

90.27 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

90.28 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
90.29 (XLR-11);

90.30 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
90.31 (AKB-48(APINACA));

90.32 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
90.33 (5-Fluoro-AKB-48);

90.34 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

90.35 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
90.36 PB-22);

91.1 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-
91.2 3-carboxamide (AB-PINACA);

91.3 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
91.4 1H-indazole-3-carboxamide (AB-FUBINACA);

9.32 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
9.33 -phenol (CP 55,940).

9.34 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
9.35 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
9.36 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
10.1 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
10.2 any extent and whether or not substituted in the phenyl ring to any extent. Examples of
10.3 benzoylindoles include, but are not limited to:

10.4 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

10.5 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

10.6 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
10.7 (WIN 48,098 or Pravadoline).

10.8 (viii) Others specifically named:

10.9 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.10 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

10.11 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.12 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

10.13 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
10.14 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

10.15 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

10.16 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
10.17 (XLR-11);

10.18 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
10.19 (AKB-48(APINACA));

10.20 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
10.21 (5-Fluoro-AKB-48);

10.22 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

10.23 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
10.24 PB-22);

10.25 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-
10.26 3-carboxamide (AB-PINACA);

10.27 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
10.28 1H-indazole-3-carboxamide (AB-FUBINACA);

- 91.5 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA);
- 91.6 indazole-3-carboxamide(AB-CHMINACA);
- 91.7 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5-fluoro-AMB);
- 91.8 methylbutanoate (5-fluoro-AMB);
- 91.9 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 91.10 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
- 91.11 (FUBIMINA);
- 91.12 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12));
- 91.13 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 91.14 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);
- 91.15 -1H-indole-3-carboxamide (5-fluoro-ABICA);
- 91.16 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
- 91.17 -1H-indole-3-carboxamide;
- 91.18 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; and
- 91.19 -1H-indazole-3-carboxamide; and
- 91.20 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate.
- 91.21 -3,3-dimethylbutanoate.
- 91.22 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended for human consumption.
- 91.23 intended for human consumption.
- 91.24 Sec. 2. Minnesota Statutes 2014, section 152.02, subdivision 3, is amended to read:
- 91.25 Subd. 3. **Schedule II.** (a) Schedule II consists of the substances listed in this subdivision.
- 91.26 subdivision.
- 91.27 (b) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 91.28 the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 91.29 substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 91.30 combination of extraction and chemical synthesis:
- 91.31 (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate.
- 91.32 or opiate.
- 91.33 (i) Excluding:
- 91.34 (A) apomorphine;
- 91.35 (B) thebaine-derived butorphanol;
- 92.1 (C) dextrophan;
- 92.2 (D) nalbuphine;

- 10.29 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA);
- 10.30 indazole-3-carboxamide(AB-CHMINACA);
- 10.31 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5-fluoro-AMB);
- 10.32 methylbutanoate (5-fluoro-AMB);
- 10.33 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 10.34 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
- 10.35 (FUBIMINA);
- 11.1 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12));
- 11.2 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 11.3 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);
- 11.4 -1H-indole-3-carboxamide (5-fluoro-ABICA);
- 11.5 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
- 11.6 -1H-indole-3-carboxamide;
- 11.7 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; and
- 11.8 -1H-indazole-3-carboxamide; and
- 11.9 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate.
- 11.10 -3,3-dimethylbutanoate.
- 11.11 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended for human consumption.
- 11.12 intended for human consumption.
- 11.13 Sec. 2. Minnesota Statutes 2014, section 152.02, subdivision 3, is amended to read:
- 11.14 Subd. 3. **Schedule II.** (a) Schedule II consists of the substances listed in this subdivision.
- 11.15 subdivision.
- 11.16 (b) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 11.17 the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 11.18 substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 11.19 combination of extraction and chemical synthesis:
- 11.20 (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate.
- 11.21 or opiate.
- 11.22 (i) Excluding:
- 11.23 (A) apomorphine;
- 11.24 (B) thebaine-derived butorphanol;
- 11.25 (C) dextrophan;
- 11.26 (D) nalbuphine;

92.3 (E) nalmefene;
 92.4 (F) naloxegol;
 92.5 ~~(F)~~ (G) naloxone;
 92.6 ~~(G)~~ (H) naltrexone; and
 92.7 ~~(H)~~ and (I) their respective salts;
 92.8 (ii) but including the following:
 92.9 (A) opium, in all forms and extracts;
 92.10 (B) codeine;
 92.11 (C) dihydroetorphine;
 92.12 (D) ethylmorphine;
 92.13 (E) etorphine hydrochloride;
 92.14 (F) hydrocodone;
 92.15 (G) hydromorphone;
 92.16 (H) metopon;
 92.17 (I) morphine;
 92.18 (J) oxycodone;
 92.19 (K) oxymorphone;
 92.20 (L) thebaine;
 92.21 (M) oripavine;
 92.22 (2) any salt, compound, derivative, or preparation thereof which is chemically
 92.23 equivalent or identical with any of the substances referred to in clause (1), except that
 92.24 these substances shall not include the isoquinoline alkaloids of opium;
 92.25 (3) opium poppy and poppy straw;
 92.26 (4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca
 92.27 leaves (including cocaine and ecgonine and their salts, isomers, derivatives, and salts
 92.28 of isomers and derivatives), and any salt, compound, derivative, or preparation thereof
 92.29 which is chemically equivalent or identical with any of these substances, except that the
 92.30 substances shall not include decocainized coca leaves or extraction of coca leaves, which
 92.31 extractions do not contain cocaine or ecgonine;
 92.32 (5) concentrate of poppy straw (the crude extract of poppy straw in either liquid,
 92.33 solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).

11.27 (E) nalmefene;
 11.28 (F) naloxegol;
 11.29 ~~(F)~~ (G) naloxone;
 11.30 ~~(G)~~ (H) naltrexone; and
 11.31 ~~(H)~~ and (I) their respective salts;
 11.32 (ii) but including the following:
 11.33 (A) opium, in all forms and extracts;
 11.34 (B) codeine;
 11.35 (C) dihydroetorphine;
 12.1 (D) ethylmorphine;
 12.2 (E) etorphine hydrochloride;
 12.3 (F) hydrocodone;
 12.4 (G) hydromorphone;
 12.5 (H) metopon;
 12.6 (I) morphine;
 12.7 (J) oxycodone;
 12.8 (K) oxymorphone;
 12.9 (L) thebaine;
 12.10 (M) oripavine;
 12.11 (2) any salt, compound, derivative, or preparation thereof which is chemically
 12.12 equivalent or identical with any of the substances referred to in clause (1), except that
 12.13 these substances shall not include the isoquinoline alkaloids of opium;
 12.14 (3) opium poppy and poppy straw;
 12.15 (4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca
 12.16 leaves (including cocaine and ecgonine and their salts, isomers, derivatives, and salts
 12.17 of isomers and derivatives), and any salt, compound, derivative, or preparation thereof
 12.18 which is chemically equivalent or identical with any of these substances, except that the
 12.19 substances shall not include decocainized coca leaves or extraction of coca leaves, which
 12.20 extractions do not contain cocaine or ecgonine;
 12.21 (5) concentrate of poppy straw (the crude extract of poppy straw in either liquid,
 12.22 solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).

92.34 (c) Any of the following opiates, including their isomers, esters, ethers, salts, and
 92.35 salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another
 93.1 schedule, whenever the existence of such isomers, esters, ethers and salts is possible
 93.2 within the specific chemical designation:

- 93.3 (1) alfentanil;
- 93.4 (2) alphaprodine;
- 93.5 (3) anileridine;
- 93.6 (4) bezitramide;
- 93.7 (5) bulk dextropropoxyphene (nondosage forms);
- 93.8 (6) carfentanil;
- 93.9 (7) dihydrocodeine;
- 93.10 (8) dihydromorphinone;
- 93.11 (9) diphenoxylate;
- 93.12 (10) fentanyl;
- 93.13 (11) isomethadone;
- 93.14 (12) levo-alpha-acetylmethadol (LAAM);
- 93.15 (13) levomethorphan;
- 93.16 (14) levorphanol;
- 93.17 (15) metazocine;
- 93.18 (16) methadone;
- 93.19 (17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 93.20 (18) moramide - intermediate, 2-methyl-3-morpholino-1,
- 93.21 1-diphenyl-propane-carboxylic acid;
- 93.22 (19) pethidine;
- 93.23 (20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
- 93.24 (21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
- 93.25 (22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 93.26 (23) phenazocine;
- 93.27 (24) piminodine;

12.23 (c) Any of the following opiates, including their isomers, esters, ethers, salts, and
 12.24 salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another
 12.25 schedule, whenever the existence of such isomers, esters, ethers and salts is possible
 12.26 within the specific chemical designation:

- 12.27 (1) alfentanil;
- 12.28 (2) alphaprodine;
- 12.29 (3) anileridine;
- 12.30 (4) bezitramide;
- 12.31 (5) bulk dextropropoxyphene (nondosage forms);
- 12.32 (6) carfentanil;
- 12.33 (7) dihydrocodeine;
- 12.34 (8) dihydromorphinone;
- 12.35 (9) diphenoxylate;
- 12.36 (10) fentanyl;
- 13.1 (11) isomethadone;
- 13.2 (12) levo-alpha-acetylmethadol (LAAM);
- 13.3 (13) levomethorphan;
- 13.4 (14) levorphanol;
- 13.5 (15) metazocine;
- 13.6 (16) methadone;
- 13.7 (17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 13.8 (18) moramide - intermediate, 2-methyl-3-morpholino-1,
- 13.9 1-diphenyl-propane-carboxylic acid;
- 13.10 (19) pethidine;
- 13.11 (20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
- 13.12 (21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
- 13.13 (22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 13.14 (23) phenazocine;
- 13.15 (24) piminodine;

93.28 (25) racemethorphan;

93.29 (26) racemorphan;

93.30 (27) remifentanil;

93.31 (28) sufentanil;

93.32 (29) tapentadol;

93.33 (30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).

93.34 (d) Unless specifically excepted or unless listed in another schedule, any material,

93.35 compound, mixture, or preparation which contains any quantity of the following

93.36 substances having a stimulant effect on the central nervous system:

94.1 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;

94.2 (2) methamphetamine, its salts, isomers, and salts of its isomers;

94.3 (3) phenmetrazine and its salts;

94.4 (4) methylphenidate;

94.5 (5) lisdexamfetamine.

94.6 (e) Unless specifically excepted or unless listed in another schedule, any material,

94.7 compound, mixture, or preparation which contains any quantity of the following

94.8 substances having a depressant effect on the central nervous system, including its salts,

94.9 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of

94.10 isomers is possible within the specific chemical designation:

94.11 (1) amobarbital;

94.12 (2) glutethimide;

94.13 (3) secobarbital;

94.14 (4) pentobarbital;

94.15 (5) phencyclidine;

94.16 (6) phencyclidine immediate precursors:

94.17 (i) 1-phenylcyclohexylamine;

94.18 (ii) 1-piperidinocyclohexanecarbonitrile;

94.19 (7) phenylacetone.

94.20 (f) Hallucinogenic substances: nabilone.

94.21 Sec. 3. Minnesota Statutes 2014, section 152.02, subdivision 4, is amended to read:

13.16 (25) racemethorphan;

13.17 (26) racemorphan;

13.18 (27) remifentanil;

13.19 (28) sufentanil;

13.20 (29) tapentadol;

13.21 (30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).

13.22 (d) Unless specifically excepted or unless listed in another schedule, any material,

13.23 compound, mixture, or preparation which contains any quantity of the following

13.24 substances having a stimulant effect on the central nervous system:

13.25 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;

13.26 (2) methamphetamine, its salts, isomers, and salts of its isomers;

13.27 (3) phenmetrazine and its salts;

13.28 (4) methylphenidate;

13.29 (5) lisdexamfetamine.

13.30 (e) Unless specifically excepted or unless listed in another schedule, any material,

13.31 compound, mixture, or preparation which contains any quantity of the following

13.32 substances having a depressant effect on the central nervous system, including its salts,

13.33 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of

13.34 isomers is possible within the specific chemical designation:

13.35 (1) amobarbital;

13.36 (2) glutethimide;

14.1 (3) secobarbital;

14.2 (4) pentobarbital;

14.3 (5) phencyclidine;

14.4 (6) phencyclidine immediate precursors:

14.5 (i) 1-phenylcyclohexylamine;

14.6 (ii) 1-piperidinocyclohexanecarbonitrile;

14.7 (7) phenylacetone.

14.8 (f) Hallucinogenic substances: nabilone.

14.9 Sec. 3. Minnesota Statutes 2014, section 152.02, subdivision 4, is amended to read:

94.22 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this
94.23 subdivision.

94.24 (b) Stimulants. Unless specifically excepted or unless listed in another schedule,
94.25 any material, compound, mixture, or preparation which contains any quantity of the
94.26 following substances having a potential for abuse associated with a stimulant effect on the
94.27 central nervous system, including its salts, isomers, and salts of such isomers whenever
94.28 the existence of such salts, isomers, and salts of isomers is possible within the specific
94.29 chemical designation:

94.30 (1) benzphetamine;

94.31 (2) chlorphentermine;

94.32 (3) clortermine;

94.33 (4) phendimetrazine.

94.34 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
94.35 any material, compound, mixture, or preparation which contains any quantity of the
95.1 following substances having a potential for abuse associated with a depressant effect on
95.2 the central nervous system:

95.3 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
95.4 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
95.5 are not listed in any schedule;

95.6 (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital,
95.7 or any salt of any of these drugs and approved by the food and drug administration for
95.8 marketing only as a suppository;

95.9 (3) any substance which contains any quantity of a derivative of barbituric acid, or
95.10 any salt of a derivative of barbituric acid, except those substances which are specifically
95.11 listed in other schedules;

95.12 (4) any drug product containing gamma hydroxybutyric acid, including its salts,
95.13 isomers, and salts of isomers, for which an application is approved under section 505 of
95.14 the federal Food, Drug, and Cosmetic Act;

95.15 (5) any of the following substances:

95.16 (i) chlorhexadol;

95.17 (ii) ketamine, its salts, isomers and salts of isomers;

95.18 (iii) lysergic acid;

95.19 (iv) lysergic acid amide;

95.20 (v) methyprylon;

14.10 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this
14.11 subdivision.

14.12 (b) Stimulants. Unless specifically excepted or unless listed in another schedule,
14.13 any material, compound, mixture, or preparation which contains any quantity of the
14.14 following substances having a potential for abuse associated with a stimulant effect on the
14.15 central nervous system, including its salts, isomers, and salts of such isomers whenever
14.16 the existence of such salts, isomers, and salts of isomers is possible within the specific
14.17 chemical designation:

14.18 (1) benzphetamine;

14.19 (2) chlorphentermine;

14.20 (3) clortermine;

14.21 (4) phendimetrazine.

14.22 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
14.23 any material, compound, mixture, or preparation which contains any quantity of the
14.24 following substances having a potential for abuse associated with a depressant effect on
14.25 the central nervous system:

14.26 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
14.27 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
14.28 are not listed in any schedule;

14.29 (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital,
14.30 or any salt of any of these drugs and approved by the food and drug administration for
14.31 marketing only as a suppository;

14.32 (3) any substance which contains any quantity of a derivative of barbituric acid, or
14.33 any salt of a derivative of barbituric acid, except those substances which are specifically
14.34 listed in other schedules;

15.1 (4) any drug product containing gamma hydroxybutyric acid, including its salts,
15.2 isomers, and salts of isomers, for which an application is approved under section 505 of
15.3 the federal Food, Drug, and Cosmetic Act;

15.4 (5) any of the following substances:

15.5 (i) chlorhexadol;

15.6 (ii) ketamine, its salts, isomers and salts of isomers;

15.7 (iii) lysergic acid;

15.8 (iv) lysergic acid amide;

15.9 (v) methyprylon;

- 95.21 (vi) sulfondiethylmethane;
- 95.22 (vii) sulfonethylmethane;
- 95.23 (viii) sulfonmethane;
- 95.24 (ix) tiletamine and zolazepam and any salt thereof;
- 95.25 (x) embutramide-;
- 95.26 (xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)
- 95.27 benzonitrile].
- 95.28 (d) Nalorphine.
- 95.29 (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
- 95.30 any material, compound, mixture, or preparation containing any of the following narcotic
- 95.31 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
- 95.32 as follows:
- 95.33 (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
- 95.34 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
- 95.35 of opium;
- 96.1 (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
- 96.2 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
- 96.3 therapeutic amounts;
- 96.4 ~~(3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not~~
- 96.5 ~~more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an~~
- 96.6 ~~isoquinoline alkaloid of opium;~~
- 96.7 ~~(4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not~~
- 96.8 ~~more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients~~
- 96.9 ~~in recognized therapeutic amounts;~~
- 96.10 ~~(5) (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more~~
- 96.11 ~~than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in~~
- 96.12 ~~recognized therapeutic amounts;~~
- 96.13 ~~(6) (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not~~
- 96.14 ~~more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients~~
- 96.15 ~~in recognized therapeutic amounts;~~
- 96.16 ~~(7) (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams,~~
- 96.17 ~~or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic~~
- 96.18 ~~ingredients in recognized therapeutic amounts;~~
- 96.19 ~~(8) (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams~~
- 96.20 ~~with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;~~

- 15.10 (vi) sulfondiethylmethane;
- 15.11 (vii) sulfonethylmethane;
- 15.12 (viii) sulfonmethane;
- 15.13 (ix) tiletamine and zolazepam and any salt thereof;
- 15.14 (x) embutramide-;
- 15.15 (xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)
- 15.16 benzonitrile].
- 15.17 (d) Nalorphine.
- 15.18 (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
- 15.19 any material, compound, mixture, or preparation containing any of the following narcotic
- 15.20 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
- 15.21 as follows:
- 15.22 (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
- 15.23 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
- 15.24 of opium;
- 15.25 (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
- 15.26 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
- 15.27 therapeutic amounts;
- 15.28 ~~(3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not~~
- 15.29 ~~more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an~~
- 15.30 ~~isoquinoline alkaloid of opium;~~
- 15.31 ~~(4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not~~
- 15.32 ~~more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients~~
- 15.33 ~~in recognized therapeutic amounts;~~
- 15.34 ~~(5) (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more~~
- 15.35 ~~than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in~~
- 15.36 ~~recognized therapeutic amounts;~~
- 16.1 ~~(6) (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not~~
- 16.2 ~~more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients~~
- 16.3 ~~in recognized therapeutic amounts;~~
- 16.4 ~~(7) (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams,~~
- 16.5 ~~or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic~~
- 16.6 ~~ingredients in recognized therapeutic amounts;~~
- 16.7 ~~(8) (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams~~
- 16.8 ~~with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;~~

96.21 (f) Anabolic steroids and, human growth hormone, and chorionic gonadotropin.

96.22 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal

96.23 substance, chemically and pharmacologically related to testosterone, other than estrogens,

96.24 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

96.25 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;

96.26 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;

96.27 (iii) androstanedione (5[alpha]-androstan-3,17-dione);

96.28 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

96.29 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

96.30 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

96.31 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

96.32 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);

96.33 (ix) 4-androstenedione (androst-4-en-3,17-dione);

96.34 (x) 5-androstenedione (androst-5-en-3,17-dione);

96.35 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

96.36 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);

97.1 (xiii) boldione (androsta-1,4-diene-3,17-dione);

97.2 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

97.3 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

97.4 (xvi) dehydrochloromethyltestosterone

97.5 (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);

97.6 (xvii) desoxymethyltestosterone

97.7 (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);

97.8 (xviii) [delta]1-dihydrotestosterone-

97.9 (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);

97.10 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);

97.11 (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);

97.12 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);

97.13 (xxii) fluoxymesterone

97.14 (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);

16.9 (f) Anabolic steroids and, human growth hormone, and chorionic gonadotropin.

16.10 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal

16.11 substance, chemically and pharmacologically related to testosterone, other than estrogens,

16.12 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

16.13 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;

16.14 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;

16.15 (iii) androstanedione (5[alpha]-androstan-3,17-dione);

16.16 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

16.17 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

16.18 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

16.19 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

16.20 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);

16.21 (ix) 4-androstenedione (androst-4-en-3,17-dione);

16.22 (x) 5-androstenedione (androst-5-en-3,17-dione);

16.23 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

16.24 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);

16.25 (xiii) boldione (androsta-1,4-diene-3,17-dione);

16.26 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

16.27 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

16.28 (xvi) dehydrochloromethyltestosterone

16.29 (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);

16.30 (xvii) desoxymethyltestosterone

16.31 (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);

16.32 (xviii) [delta]1-dihydrotestosterone-

16.33 (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);

16.34 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);

16.35 (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);

16.36 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);

17.1 (xxii) fluoxymesterone

17.2 (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);

97.15 (xxiii) formebolone
 97.16 (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
 97.17 (xxiv) furazabol
 97.18 (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
 97.19 -hydroxygon-4-en-3-one;
 97.20 (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
 97.21 (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
 97.22 (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-3-one);
 97.23 (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-3-one);
 97.24 (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
 97.25 (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
 97.26 (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androst-17beta-ol-3-one)
 97.27 (~~xxxii~~) (xxxii) methenolone
 97.28 (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
 97.29 (~~xxxiii~~) (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
 97.30 (~~xxxiiii~~) (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
 97.31 (~~xxxiv~~) (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
 97.32 (~~xxxv~~) (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone
 97.33 (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
 97.34 (~~xxxvi~~) (xxxvii) methyldienolone
 97.35 (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
 98.1 (~~xxxvii~~) (xxxviii) methyltrienolone
 98.2 (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
 98.3 (~~xxxviii~~) (xxxix) methyltestosterone
 98.4 (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
 98.5 (~~xxxix~~) (xl) mibolerone
 98.6 (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
 98.7 (~~xl~~) (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
 98.8 (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
 98.9 (~~xli~~) (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
 98.10 (~~xlii~~) (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene);

17.3 (xxiii) formebolone
 17.4 (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
 17.5 (xxiv) furazabol
 17.6 (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
 17.7 -hydroxygon-4-en-3-one;
 17.8 (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
 17.9 (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
 17.10 (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-3-one);
 17.11 (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-3-one);
 17.12 (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
 17.13 (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
 17.14 (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androst-17beta-ol-3-one)
 17.15 (~~xxxii~~) (xxxii) methenolone
 17.16 (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
 17.17 (~~xxxiii~~) (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
 17.18 (~~xxxiiii~~) (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
 17.19 (~~xxxiv~~) (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
 17.20 (~~xxxv~~) (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone
 17.21 (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
 17.22 (~~xxxvi~~) (xxxvii) methyldienolone
 17.23 (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
 17.24 (~~xxxvii~~) (xxxviii) methyltrienolone
 17.25 (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
 17.26 (~~xxxviii~~) (xxxix) methyltestosterone
 17.27 (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
 17.28 (~~xxxix~~) (xl) mibolerone
 17.29 (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
 17.30 (~~xl~~) (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
 17.31 (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
 17.32 (~~xli~~) (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
 17.33 (~~xlii~~) (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene);

- 98.11 ~~(xliv)~~ (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
 98.12 (3[beta],17[beta]-dihydroxyestr-5-ene);
 98.13 ~~(xlv)~~ (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
 98.14 ~~(xlv)~~ (xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
 98.15 ~~(xlv)~~ (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 98.16 ~~(xlvii)~~ (xlviii) norbolethone
 98.17 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
 98.18 ~~(xlviii)~~ (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
 98.19 ~~(xlix)~~ (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
 98.20 (l) (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
 98.21 (li) (lii) oxandrolone
 98.22 (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
 98.23 (lii) (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
 98.24 (liii) (liv) oxymetholone
 98.25 (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
 98.26 (lv) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole
 98.27 ~~(liv)~~ (lvi) stanozolol
 98.28 (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
 98.29 ~~(lv)~~ (lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
 98.30 ~~(lvii)~~ (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
 98.31 acid lactone);
 98.32 ~~(lviii)~~ (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
 98.33 ~~(lviii)~~ (lx) tetrahydrogestrinone
 98.34 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
 98.35 ~~(lix)~~ (lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
 98.36 ~~(lx)~~ (lxii) any salt, ester, or ether of a drug or substance described in this paragraph.
 99.1 Anabolic steroids are not included if they are: (A) expressly intended for administration
 99.2 through implants to cattle or other nonhuman species; and (B) approved by the United
 99.3 States Food and Drug Administration for that use;
 99.4 (2) Human growth hormones.
 99.5 (3) Chorionic gonadotropin.

- 17.34 ~~(xliv)~~ (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
 17.35 (3[beta],17[beta]-dihydroxyestr-5-ene);
 17.36 ~~(xlv)~~ (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
 18.1 ~~(xlv)~~ (xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
 18.2 ~~(xlv)~~ (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 18.3 ~~(xlvii)~~ (xlviii) norbolethone
 18.4 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
 18.5 ~~(xlviii)~~ (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
 18.6 ~~(xlix)~~ (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
 18.7 (l) (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
 18.8 (li) (lii) oxandrolone
 18.9 (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
 18.10 (lii) (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
 18.11 (liii) (liv) oxymetholone
 18.12 (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
 18.13 (lv) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole
 18.14 ~~(liv)~~ (lvi) stanozolol
 18.15 (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
 18.16 ~~(lv)~~ (lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
 18.17 ~~(lvii)~~ (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
 18.18 acid lactone);
 18.19 ~~(lviii)~~ (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
 18.20 ~~(lviii)~~ (lx) tetrahydrogestrinone
 18.21 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
 18.22 ~~(lix)~~ (lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
 18.23 ~~(lx)~~ (lxii) any salt, ester, or ether of a drug or substance described in this paragraph.
 18.24 Anabolic steroids are not included if they are: (A) expressly intended for administration
 18.25 through implants to cattle or other nonhuman species; and (B) approved by the United
 18.26 States Food and Drug Administration for that use;
 18.27 (2) Human growth hormones.
 18.28 (3) Chorionic gonadotropin.

99.6 (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated
99.7 in a soft gelatin capsule in a United States Food and Drug Administration approved product.

99.8 (h) Any material, compound, mixture, or preparation containing the following
99.9 narcotic drug or its salt: buprenorphine.

99.10 Sec. 4. Minnesota Statutes 2014, section 152.02, subdivision 5, is amended to read:

99.11 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this
99.12 subdivision.

99.13 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
99.14 any material, compound, mixture, or preparation containing any of the following narcotic
99.15 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
99.16 as follows:

99.17 (1) not more than one milligram of difenoxin and not less than 25 micrograms of
99.18 atropine sulfate per dosage unit;

99.19 (2) dextropropoxyphene (Darvon and Darvocet);

99.20 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical
99.21 and geometric isomers, and salts of these isomers (including tramadol).

99.22 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
99.23 any material, compound, mixture, or preparation containing any quantity of the following
99.24 substances, including its salts, isomers, and salts of isomers whenever the existence of the
99.25 salts, isomers, and salts of isomers is possible:

99.26 (1) Alfaxalone (5 α -pregnan-3 α -ol-11,20-dione);

99.27 (1) (2) alprazolam;

99.28 (2) (3) barbital;

99.29 (3) (4) bromazepam;

99.30 (4) (5) camazepam;

99.31 (5) (6) carisoprodol;

99.32 (6) (7) chloral betaine;

99.33 (7) (8) chloral hydrate;

99.34 (8) (9) chlordiazepoxide;

99.35 (9) (10) clobazam;

100.1 (10) (11) clonazepam;

100.2 (11) (12) clorazepate;

18.29 (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated
18.30 in a soft gelatin capsule in a United States Food and Drug Administration approved product.

18.31 (h) Any material, compound, mixture, or preparation containing the following
18.32 narcotic drug or its salt: buprenorphine.

18.33 Sec. 4. Minnesota Statutes 2014, section 152.02, subdivision 5, is amended to read:

18.34 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this
18.35 subdivision.

19.1 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
19.2 any material, compound, mixture, or preparation containing any of the following narcotic
19.3 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
19.4 as follows:

19.5 (1) not more than one milligram of difenoxin and not less than 25 micrograms of
19.6 atropine sulfate per dosage unit;

19.7 (2) dextropropoxyphene (Darvon and Darvocet);

19.8 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical
19.9 and geometric isomers, and salts of these isomers (including tramadol).

19.10 (c) Depressants. Unless specifically excepted or unless listed in another schedule,
19.11 any material, compound, mixture, or preparation containing any quantity of the following
19.12 substances, including its salts, isomers, and salts of isomers whenever the existence of the
19.13 salts, isomers, and salts of isomers is possible:

19.14 (1) Alfaxalone (5 α -pregnan-3 α -ol-11,20-dione);

19.15 (1) (2) alprazolam;

19.16 (2) (3) barbital;

19.17 (3) (4) bromazepam;

19.18 (4) (5) camazepam;

19.19 (5) (6) carisoprodol;

19.20 (6) (7) chloral betaine;

19.21 (7) (8) chloral hydrate;

19.22 (8) (9) chlordiazepoxide;

19.23 (9) (10) clobazam;

19.24 (10) (11) clonazepam;

19.25 (11) (12) clorazepate;

100.3 ~~(12)~~ (13) clonazepam;
 100.4 ~~(13)~~ (14) clonazepam;
 100.5 ~~(14)~~ (15) delorazepam;
 100.6 ~~(15)~~ (16) diazepam;
 100.7 ~~(16)~~ (17) dichloralphenazone;
 100.8 ~~(17)~~ (18) estazolam;
 100.9 ~~(18)~~ (19) ethchlorvynol;
 100.10 ~~(19)~~ (20) ethinamate;
 100.11 ~~(20)~~ (21) ethyl loflazepate;
 100.12 ~~(21)~~ (22) fludiazepam;
 100.13 ~~(22)~~ (23) flurazepam;
 100.14 (24) fospropofol
 100.15 ~~(23)~~ (25) halazepam;
 100.16 ~~(24)~~ (26) haloxazolam;
 100.17 ~~(25)~~ (27) ketazolam;
 100.18 ~~(26)~~ (28) lorazepam;
 100.19 ~~(27)~~ (29) lorazepam;
 100.20 ~~(28)~~ (30) lorazepam mebutamate;
 100.21 ~~(29)~~ (31) medazepam;
 100.22 ~~(30)~~ (32) meprobamate;
 100.23 ~~(31)~~ (33) methohexital;
 100.24 ~~(32)~~ (34) methylphenobarbital;
 100.25 ~~(33)~~ (35) midazolam;
 100.26 ~~(34)~~ (36) nimetazepam;
 100.27 ~~(35)~~ (37) nitrazepam ~~nordiazepam~~ (37) nitrazepam;
 100.28 (38) nordiazepam;
 100.29 ~~(36)~~ (39) oxazepam;
 100.30 ~~(37)~~ (40) oxazolam;

19.26 ~~(12)~~ (13) clonazepam;
 19.27 ~~(13)~~ (14) clonazepam;
 19.28 ~~(14)~~ (15) delorazepam;
 19.29 ~~(15)~~ (16) diazepam;
 19.30 ~~(16)~~ (17) dichloralphenazone;
 19.31 ~~(17)~~ (18) estazolam;
 19.32 ~~(18)~~ (19) ethchlorvynol;
 19.33 ~~(19)~~ (20) ethinamate;
 19.34 ~~(20)~~ (21) ethyl loflazepate;
 19.35 ~~(21)~~ (22) fludiazepam;
 19.36 ~~(22)~~ (23) flurazepam;
 20.1 (24) fospropofol
 20.2 ~~(23)~~ (25) halazepam;
 20.3 ~~(24)~~ (26) haloxazolam;
 20.4 ~~(25)~~ (27) ketazolam;
 20.5 ~~(26)~~ (28) lorazepam;
 20.6 ~~(27)~~ (29) lorazepam;
 20.7 ~~(28)~~ (30) lorazepam mebutamate;
 20.8 ~~(29)~~ (31) medazepam;
 20.9 ~~(30)~~ (32) meprobamate;
 20.10 ~~(31)~~ (33) methohexital;
 20.11 ~~(32)~~ (34) methylphenobarbital;
 20.12 ~~(33)~~ (35) midazolam;
 20.13 ~~(34)~~ (36) nimetazepam;
 20.14 ~~(35)~~ (37) nitrazepam ~~nordiazepam~~ (37) nitrazepam;
 20.15 (38) nordiazepam;
 20.16 ~~(36)~~ (39) oxazepam;
 20.17 ~~(37)~~ (40) oxazolam;

100.31 ~~(38) paraldehyde~~~~petrichloral~~ (41) paraldehyde;

100.32 (42) petrichloral;

100.33 ~~(39)~~ (43) phenobarbital;

100.34 ~~(40)~~ (44) pinazepam;

100.35 (41) (45) prazepam;

100.36 ~~(42)~~ (46) quazepam;

101.1 (47) Suvorexant;

101.2 ~~(43)~~ (48) temazepam;

101.3 ~~(44)~~ (49) tetrazepam;

101.4 ~~(45)~~ (50) triazolam;

101.5 ~~(46)~~ (51) zaleplon;

101.6 ~~(47)~~ (52) zolpidem;

101.7 ~~(48)~~ (53) zopiclone.

101.8 (d) Any material, compound, mixture, or preparation which contains any quantity of
101.9 the following substance including its salts, isomers, and salts of such isomers, whenever
101.10 the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.

101.11 (e) Stimulants. Unless specifically excepted or unless listed in another schedule,
101.12 any material, compound, mixture, or preparation which contains any quantity of the
101.13 following substances having a stimulant effect on the central nervous system, including its
101.14 salts, isomers, and salts of isomers:

101.15 (1) cathine (norpseudoephedrine);

101.16 (2) diethylpropion;

101.17 (3) fencamfamine;

101.18 (4) fenproporex;

101.19 (5) mazindol;

101.20 (6) mefenorex;

101.21 (7) modafinil;

101.22 (8) pemoline (including organometallic complexes and chelates thereof);

101.23 (9) phentermine;

101.24 (10) pipradol;

20.18 ~~(38)~~ (41) paraldehyde~~petrichloral~~ paraldehyde;

20.19 (42) petrichloral;

20.20 ~~(39)~~ (43) phenobarbital;

20.21 ~~(40)~~ (44) pinazepam;

20.22 (41) (45) prazepam;

20.23 ~~(42)~~ (46) quazepam;

20.24 (47) Suvorexant;

20.25 ~~(43)~~ (48) temazepam;

20.26 ~~(44)~~ (49) tetrazepam;

20.27 ~~(45)~~ (50) triazolam;

20.28 ~~(46)~~ (51) zaleplon;

20.29 ~~(47)~~ (52) zolpidem;

20.30 ~~(48)~~ (53) zopiclone.

20.31 (d) Any material, compound, mixture, or preparation which contains any quantity of
20.32 the following substance including its salts, isomers, and salts of such isomers, whenever
20.33 the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.

20.34 (e) Stimulants. Unless specifically excepted or unless listed in another schedule,
20.35 any material, compound, mixture, or preparation which contains any quantity of the
21.1 following substances having a stimulant effect on the central nervous system, including its
21.2 salts, isomers, and salts of isomers:

21.3 (1) cathine (norpseudoephedrine);

21.4 (2) diethylpropion;

21.5 (3) fencamfamine;

21.6 (4) fenproporex;

21.7 (5) mazindol;

21.8 (6) mefenorex;

21.9 (7) modafinil;

21.10 (8) pemoline (including organometallic complexes and chelates thereof);

21.11 (9) phentermine;

21.12 (10) pipradol;

101.25 (11) sibutramine;

101.26 (12) SPA (1-dimethylamino-1,2-diphenylethane).

101.27 (f) lorcaserin.

101.28 Sec. 5. Minnesota Statutes 2014, section 152.02, subdivision 6, is amended to read:

101.29 Subd. 6. **Schedule V; restrictions on methamphetamine precursor drugs.** (a) As
101.30 used in this subdivision, the following terms have the meanings given:

101.31 (1) "methamphetamine precursor drug" means any compound, mixture, or
101.32 preparation intended for human consumption containing ephedrine or pseudoephedrine as
101.33 its sole active ingredient or as one of its active ingredients; and

101.34 (2) "over-the-counter sale" means a retail sale of a drug or product but does not
101.35 include the sale of a drug or product pursuant to the terms of a valid prescription.

102.1 (b) The following items are listed in Schedule V:

102.2 (1) any compound, mixture, or preparation containing any of the following limited
102.3 quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
102.4 ingredients in sufficient proportion to confer upon the compound, mixture or preparation
102.5 valuable medicinal qualities other than those possessed by the narcotic drug alone:

102.6 (i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
102.7 grams;

102.8 (ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
102.9 grams;

102.10 (iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
102.11 of atropine sulfate per dosage unit;

102.12 (iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or

102.13 (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of
102.14 atropine sulfate per dosage unit.

102.15 (2) Stimulants. Unless specifically exempted or excluded or unless listed in another
102.16 schedule, any material, compound, mixture, or preparation that contains any quantity of
102.17 the following substance having a stimulant effect on the central nervous system, including
102.18 its salts, isomers, and salts of isomers: pyrovalerone.

102.19 (3) Depressants. Unless specifically exempted or excluded or unless listed in another
102.20 schedule, any material, compound, mixture, or preparation that contains any quantity
102.21 of the following substance having a depressant effect on the central nervous system,
102.22 including its salts, isomers, and salts of isomers:

102.23 (i) ezogabine;

21.13 (11) sibutramine;

21.14 (12) SPA (1-dimethylamino-1,2-diphenylethane).

21.15 (f) lorcaserin.

21.16 Sec. 5. Minnesota Statutes 2014, section 152.02, subdivision 6, is amended to read:

21.17 Subd. 6. **Schedule V; restrictions on methamphetamine precursor drugs.** (a) As
21.18 used in this subdivision, the following terms have the meanings given:

21.19 (1) "methamphetamine precursor drug" means any compound, mixture, or
21.20 preparation intended for human consumption containing ephedrine or pseudoephedrine as
21.21 its sole active ingredient or as one of its active ingredients; and

21.22 (2) "over-the-counter sale" means a retail sale of a drug or product but does not
21.23 include the sale of a drug or product pursuant to the terms of a valid prescription.

21.24 (b) The following items are listed in Schedule V:

21.25 (1) any compound, mixture, or preparation containing any of the following limited
21.26 quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
21.27 ingredients in sufficient proportion to confer upon the compound, mixture or preparation
21.28 valuable medicinal qualities other than those possessed by the narcotic drug alone:

21.29 (i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
21.30 grams;

21.31 (ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
21.32 grams;

21.33 (iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
21.34 of atropine sulfate per dosage unit;

21.35 (iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or

22.1 (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of
22.2 atropine sulfate per dosage unit.

22.3 (2) Stimulants. Unless specifically exempted or excluded or unless listed in another
22.4 schedule, any material, compound, mixture, or preparation that contains any quantity of
22.5 the following substance having a stimulant effect on the central nervous system, including
22.6 its salts, isomers, and salts of isomers: pyrovalerone.

22.7 (3) Depressants. Unless specifically exempted or excluded or unless listed in another
22.8 schedule, any material, compound, mixture, or preparation that contains any quantity
22.9 of the following substance having a depressant effect on the central nervous system,
22.10 including its salts, isomers, and salts of isomers:

22.11 (i) ezogabine;

102.24 ~~(i)~~ (ii) pregabalin;

102.25 ~~(ii)~~ (iii) lacosamide.

102.26 (4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine
102.27 as its sole active ingredient or as one of its active ingredients.

102.28 (c) No person may sell in a single over-the-counter sale more than two packages of a
102.29 methamphetamine precursor drug or a combination of methamphetamine precursor drugs or
102.30 any combination of packages exceeding a total weight of six grams, calculated as the base.

102.31 (d) Over-the-counter sales of methamphetamine precursor drugs are limited to:

102.32 (1) packages containing not more than a total of three grams of one or
102.33 more methamphetamine precursor drugs, calculated in terms of ephedrine base or
102.34 pseudoephedrine base; or

103.1 (2) for nonliquid products, sales in blister packs, where each blister contains not
103.2 more than two dosage units, or, if the use of blister packs is not technically feasible, sales
103.3 in unit dose packets or pouches.

103.4 (e) A business establishment that offers for sale methamphetamine precursor drugs
103.5 in an over-the-counter sale shall ensure that all packages of the drugs are displayed
103.6 behind a checkout counter where the public is not permitted and are offered for sale only
103.7 by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The
103.8 establishment shall ensure that the person making the sale requires the buyer:

103.9 (1) to provide photographic identification showing the buyer's date of birth; and

103.10 (2) to sign a written or electronic document detailing the date of the sale, the name
103.11 of the buyer, and the amount of the drug sold.

103.12 A document described under clause (2) must be retained by the establishment for
103.13 at least three years and must at all reasonable times be open to the inspection of any
103.14 law enforcement agency.

103.15 Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
103.16 purchase.

103.17 (f) No person may acquire through over-the-counter sales more than six grams of
103.18 methamphetamine precursor drugs, calculated as the base, within a 30-day period.

103.19 (g) No person may sell in an over-the-counter sale a methamphetamine precursor
103.20 drug to a person under the age of 18 years. It is an affirmative defense to a charge under
103.21 this paragraph if the defendant proves by a preponderance of the evidence that the
103.22 defendant reasonably and in good faith relied on proof of age as described in section
103.23 340A.503, subdivision 6.

22.12 ~~(i)~~ (ii) pregabalin;

22.13 ~~(ii)~~ (iii) lacosamide.

22.14 (4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine
22.15 as its sole active ingredient or as one of its active ingredients.

22.16 (c) No person may sell in a single over-the-counter sale more than two packages of a
22.17 methamphetamine precursor drug or a combination of methamphetamine precursor drugs or
22.18 any combination of packages exceeding a total weight of six grams, calculated as the base.

22.19 (d) Over-the-counter sales of methamphetamine precursor drugs are limited to:

22.20 (1) packages containing not more than a total of three grams of one or
22.21 more methamphetamine precursor drugs, calculated in terms of ephedrine base or
22.22 pseudoephedrine base; or

22.23 (2) for nonliquid products, sales in blister packs, where each blister contains not
22.24 more than two dosage units, or, if the use of blister packs is not technically feasible, sales
22.25 in unit dose packets or pouches.

22.26 (e) A business establishment that offers for sale methamphetamine precursor drugs
22.27 in an over-the-counter sale shall ensure that all packages of the drugs are displayed
22.28 behind a checkout counter where the public is not permitted and are offered for sale only
22.29 by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The
22.30 establishment shall ensure that the person making the sale requires the buyer:

22.31 (1) to provide photographic identification showing the buyer's date of birth; and

22.32 (2) to sign a written or electronic document detailing the date of the sale, the name
22.33 of the buyer, and the amount of the drug sold.

22.34 A document described under clause (2) must be retained by the establishment for
22.35 at least three years and must at all reasonable times be open to the inspection of any
22.36 law enforcement agency.

23.1 Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
23.2 purchase.

23.3 (f) No person may acquire through over-the-counter sales more than six grams of
23.4 methamphetamine precursor drugs, calculated as the base, within a 30-day period.

23.5 (g) No person may sell in an over-the-counter sale a methamphetamine precursor
23.6 drug to a person under the age of 18 years. It is an affirmative defense to a charge under
23.7 this paragraph if the defendant proves by a preponderance of the evidence that the
23.8 defendant reasonably and in good faith relied on proof of age as described in section
23.9 340A.503, subdivision 6.

103.24 (h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of
 103.25 a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
 103.26 payment of a fine of not more than \$1,000, or both.

103.27 (i) An owner, operator, supervisor, or manager of a business establishment that
 103.28 offers for sale methamphetamine precursor drugs whose employee or agent is convicted of
 103.29 or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal
 103.30 penalties for violating any of those paragraphs if the person:

103.31 (1) did not have prior knowledge of, participate in, or direct the employee or agent to
 103.32 commit the violation; and

103.33 (2) documents that an employee training program was in place to provide the
 103.34 employee or agent with information on the state and federal laws and regulations regarding
 103.35 methamphetamine precursor drugs.

104.1 (j) Any person employed by a business establishment that offers for sale
 104.2 methamphetamine precursor drugs who sells such a drug to any person in a suspicious
 104.3 transaction shall report the transaction to the owner, supervisor, or manager of the
 104.4 establishment. The owner, supervisor, or manager may report the transaction to local law
 104.5 enforcement. A person who reports information under this subdivision in good faith is
 104.6 immune from civil liability relating to the report.

104.7 (k) Paragraphs (b) to (j) do not apply to:

104.8 (1) pediatric products labeled pursuant to federal regulation primarily intended for
 104.9 administration to children under 12 years of age according to label instructions;

104.10 (2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
 104.11 being manufactured in a manner that prevents the drug from being used to manufacture
 104.12 methamphetamine;

104.13 (3) methamphetamine precursor drugs in gel capsule or liquid form; or

104.14 (4) compounds, mixtures, or preparations in powder form where pseudoephedrine
 104.15 constitutes less than one percent of its total weight and is not its sole active ingredient.

104.16 (l) The Board of Pharmacy, in consultation with the Department of Public Safety,
 104.17 shall certify methamphetamine precursor drugs that meet the requirements of paragraph
 104.18 (k), clause (2), and publish an annual listing of these drugs.

104.19 (m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
 104.20 pursuant to sections 151.42 to 151.51 and registered with and regulated by the United
 104.21 States Drug Enforcement Administration are exempt from the methamphetamine precursor
 104.22 drug storage requirements of this section.

23.10 (h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of
 23.11 a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
 23.12 payment of a fine of not more than \$1,000, or both.

23.13 (i) An owner, operator, supervisor, or manager of a business establishment that
 23.14 offers for sale methamphetamine precursor drugs whose employee or agent is convicted of
 23.15 or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal
 23.16 penalties for violating any of those paragraphs if the person:

23.17 (1) did not have prior knowledge of, participate in, or direct the employee or agent to
 23.18 commit the violation; and

23.19 (2) documents that an employee training program was in place to provide the
 23.20 employee or agent with information on the state and federal laws and regulations regarding
 23.21 methamphetamine precursor drugs.

23.22 (j) Any person employed by a business establishment that offers for sale
 23.23 methamphetamine precursor drugs who sells such a drug to any person in a suspicious
 23.24 transaction shall report the transaction to the owner, supervisor, or manager of the
 23.25 establishment. The owner, supervisor, or manager may report the transaction to local law
 23.26 enforcement. A person who reports information under this subdivision in good faith is
 23.27 immune from civil liability relating to the report.

23.28 (k) Paragraphs (b) to (j) do not apply to:

23.29 (1) pediatric products labeled pursuant to federal regulation primarily intended for
 23.30 administration to children under 12 years of age according to label instructions;

23.31 (2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
 23.32 being manufactured in a manner that prevents the drug from being used to manufacture
 23.33 methamphetamine;

23.34 (3) methamphetamine precursor drugs in gel capsule or liquid form; or

23.35 (4) compounds, mixtures, or preparations in powder form where pseudoephedrine
 23.36 constitutes less than one percent of its total weight and is not its sole active ingredient.

24.1 (l) The Board of Pharmacy, in consultation with the Department of Public Safety,
 24.2 shall certify methamphetamine precursor drugs that meet the requirements of paragraph
 24.3 (k), clause (2), and publish an annual listing of these drugs.

24.4 (m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
 24.5 pursuant to sections 151.42 to 151.51 and registered with and regulated by the United
 24.6 States Drug Enforcement Administration are exempt from the methamphetamine precursor
 24.7 drug storage requirements of this section.

104.23 (n) This section preempts all local ordinances or regulations governing the sale
104.24 by a business establishment of over-the-counter products containing ephedrine or
104.25 pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.

24.8 (n) This section preempts all local ordinances or regulations governing the sale
24.9 by a business establishment of over-the-counter products containing ephedrine or
24.10 pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.